Management of Clostridium difficile infection: thinking inside and outside the box.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Infectious Diseases

• Publication date

  2010-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/657116PMID 20979491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

  2010cited by this paper
• Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole.

  2010cited by this paper
• Treatment with monoclonal antibodies against Clostridium difficile toxins.

  2010cited by this paper
• Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature.

  2010cited by this paper
• Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection

  2009cited by this paper
• Fecal bacteriotherapy for recurrent Clostridium difficile infection.

  2009cited by this paper
• The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review.

  2009cited by this paper
• Toxin B is essential for virulence of Clostridium difficile

  2009cited by this paper
• Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.

  2009cited by this paper
• Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.

  2009cited by this paper
• Effect of Concomitant Antibiotics on Treatment of Clostridium difficile (CDI) Infection with Fidaxomicin or Vancomycin

  2009cited by this paper
• Age, Serum Albumin, and Leukocytosis/Fever Predict Clinical Outcomes of Clostridium difficile Infection Treated with Fidaxomicin and Vancomycin

  2009cited by this paper
• Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections.

  2009cited by this paper
• Alternative strategies for Clostridium difficile infection.

  2009cited by this paper
• Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study

  2009cited by this paper
• The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy.

  2009cited by this paper
• Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.

  2009cited by this paper
• Tolevamer, an Anionic Polymer, Neutralizes Toxins Produced by the BI/027 Strains of Clostridium difficile

  2008cited by this paper
• Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

  2008cited by this paper
• A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial

  2008cited by this paper
• Results of a phase Iii trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea

  2008cited by this paper
• Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

  2008cited by this paper
• OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

  2008cited by this paper
• Comparison of Clinical and Microbiological Response to Treatment of Clostridium difficile–Associated Disease with Metronidazole and Vancomycin

  2008cited by this paper
• Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea.

  2007cited by this paper
• Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system.

  2007cited by this paper
• Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses

  2007cited by this paper
• Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.

  2007cited by this paper
• Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.

  2007cited by this paper
• A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

  2007cited by this paper
• Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea.

  2006cited by this paper
• Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters

  2006cited by this paper
• Nitazoxanide for the treatment of Clostridium difficile colitis.

  2006cited by this paper
• Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

  2006cited by this paper
• Intravenous Immunoglobulin for the Treatment of Severe, Refractory, and Recurrent Clostridium difficile Diarrhea

  2006cited by this paper
• Review article: tolevamer, a novel toxin‐binding polymer: overview of preclinical pharmacology and physicochemical properties

  2006cited by this paper
• Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

  2005cited by this paper
• Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.

  2005cited by this paper
• Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.

  2005cited by this paper
• Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

  2005cited by this paper
• Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.

  2005cited by this paper
• A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea.

  2004cited by this paper
• Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea.

  2004cited by this paper
• Factors Associated With Failure of Metronidazole in Clostridium difficile–associated Disease

  2004cited by this paper
• Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin A

  2003cited by this paper
• Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

  2001cited by this paper
• GT160-246, a Toxin Binding Polymer for Treatment ofClostridium difficile Colitis

  2001cited by this paper
• Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults

  2001cited by this paper
• Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

  2000cited by this paper
• Colonization for the prevention of Clostridium difficile disease in hamsters.

  1999cited by this paper
• Bovine immunoglobulin concentrate-Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine

  1999cited by this paper
• Antibodies to Recombinant Clostridium difficile Toxins A and B Are an Effective Treatment and Prevent Relapse of C. difficile-Associated Disease in a Hamster Model of Infection

  1998cited by this paper
• Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea.

  1998cited by this paper
• Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

  1997cited by this paper
• Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract

  1997cited by this paper
• Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.

  1996cited by this paper
• Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins

  1996cited by this paper
• Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters

  1995cited by this paper
• Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis.

  1994cited by this paper
• Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

  1992cited by this paper
• Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

  1991cited by this paper
• Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate

  1991cited by this paper
• Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients.

  1989cited by this paper
• Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.

  1987cited by this paper
• Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study.

  1986cited by this paper
• Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial.

  1986cited by this paper
• Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains.

  1985cited by this paper
• Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile.

  1983cited by this paper
• Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

  1983cited by this paper
• Randomized controlled trial of colestipol in antibiotic‐associated colitis

  1982cited by this paper

• Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent

  2025cites this paper
• Clostridioides difficile is a Bacterial Priority Pathogen.

  2025cites this paper
• Chemical genetic analysis of enoxolone inhibition of Clostridioides difficile toxin production reveals adenine deaminase and ATP synthase as antivirulence targets

  2024cites this paper
• Gut Microbiota and Clostridium difficile: What We Know and the New Frontiers

  2022cites this paper
• The licorice metabolite enoxolone attenuates Clostridioides difficile pathophysiology by corrupting its metabolic and toxin production networks

  2022cites this paper
• Fecal Mycobiota Combined with Host Immune Factors Distinguish Clostridioides difficile Infection from Asymptomatic Carriage.

  2021cites this paper
• Efficacy of Routine Fecal Microbiota Transplantation for Treatment of Recurrent Clostridium difficile Infection: A Retrospective Cohort Study

  2019cites this paper
• Role of Asymptomatic Carriers in Long-Term Care Facility Clostridioides (Clostridium) difficile Transmission

  2019cites this paper
• Emerging drugs for the treatment of clostridium difficile

  2019influential citation
• Clostridium difficile Colitis Prevention and Treatment.

  2019cites this paper
• Infection and Drug Resistance Dovepress

  2019cites this paper
• High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.

  2017cites this paper
• Clostridium difficile infection in the elderly: an update on management

  2017cites this paper
• Toxin-positive Clostridium difficile latently infect mouse colonies and protect against highly pathogenic C. difficile

  2017cites this paper
• Die Rolle des intestinalen Mikrobioms bei der Überwindung und Wiederherstellung der Kolonisierungsresistenz im Mausmodell der intestinalen Kolonisierung durch Pseudomonas aeruginosa

  2017cites this paper
• Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study.

  2016cites this paper
• A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee

  2016cites this paper
• Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model

  2016cites this paper
• Interspecies Interactions between Clostridium difficile and Candida albicans

  2016cites this paper
• Molecular characterization of nosocomial infections: an Italian (KPC-producing Klebsiella pneumoniae) and a Spanish (Clostridium difficile ribotype 027) experience

  2016cites this paper
• Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings

  2016cites this paper
• Gender Differences in Non-Toxigenic Clostridium difficile Colonization and Risk of Subsequent C. difficile Infection.

  2015cites this paper
• A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model

  2015cites this paper
• SpoIIID‐mediated regulation of σK function during Clostridium difficile sporulation

  2015cites this paper
• Estudio de la infección "Clostridium difficile": incidencia, epidemiología, características clínicas, factores de riesgo de gravedad y recurrencia

  2015cites this paper
• Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

  2015influential citation
• Treatment of Clostridium difficile infection in pediatric patients

  2015cites this paper
• Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000-2012.

  2015cites this paper
• New Drugs and Strategies for Management of Clostridium difficile Colitis

  2014cites this paper
• Kibdelomycin Is a Potent and Selective Agent against Toxigenic Clostridium difficile

  2014cites this paper
• Clostridium difficile and the microbiota.

  2014cites this paper
• A Review of the Economics of Treating Clostridium difficile Infection

  2014cites this paper
• Reinforcement of the intestinal mucus layer protects against Clostridium difficile intestinal injury in vitro.

  2014cites this paper
• Colitis Clostridium difficile New Drugs and Strategies for Management of

  2014cites this paper
• Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response

  2014cites this paper
• Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence

  2014cites this paper
• [Infections caused by Clostridium difficile].

  2013cites this paper
• Fecal Transplantation for the Treatment of Recurrent Clostridium Difficile Infection

  2013cites this paper
• Clostridium difficile infections in elderly patients

  2013influential citation
• Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates

  2013cites this paper
• Therapy of Clostridium difficile infection: perspectives on a changing paradigm

  2013cites this paper
• Novel avenues for Clostridium difficile infection drug discovery

  2013cites this paper
• Clostridium difficile -associated Diarrhea: Brief Review and Update of Medical Management

  2013cites this paper
• Mortality in Clostridium difficile infection: a prospective analysis of risk predictors

  2013cites this paper
• Overview of Clostridium difficile infection: implications for China

  2013cites this paper
• Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence

  2013cites this paper
• Clostridium difficile Infection in children.

  2013influential citation
• Mechanisms of action and applications of probiotics for the treatment of Clostridium difficile infection

  2013cites this paper
• Clostridium difficile Infections and their Treatment

  2013cites this paper
• Épidémiologie des infections à Clostridium difficile chez les patients hospitalisés dans un centre hospitalo-universitaire

  2013cites this paper
• Brief Primer on Clostridium difficile Infection Costs, Reimbursement, and Government Regulation

  2013cites this paper
• Infección por Clostridium difficile en ancianos

  2013cites this paper
• Formación médica continuada: Infección nosocomial. Fundamentos y actuación clínica Infecciones producidas por Clostridium difficile

  2013cites this paper
• Fecal microbiota transplantation--an old therapy comes of age.

  2013cites this paper
• Clostridium difficile: expression of virulence factors, resistance to disinfectants and interactions with human cells

  2012cites this paper
• Immunotherapies in infectious diseases.

  2012cites this paper
• Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.

  2012cites this paper
• Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review.

  2012cites this paper
• Clostridium difficile Colitis: A Review

  2012cites this paper
• Clostridium difficile Toxins: Mediators of Inflammation

  2012cites this paper
• Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin

  2012cites this paper
• Clostridium difficile: novel insights on an incessantly challenging disease

  2012cites this paper
• Novel management strategies in the treatment of severe Clostridium difficile infection.

  2012cites this paper
• Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

  2012cites this paper
• Clostridium difficile infection in older adults: a review and update on its management.

  2012cites this paper
• Association of decreased serum protein fractions with Clostridium difficile infection in the acute care setting: a case-control study.

  2012cites this paper
• An Overview of the Diagnosis and Management of Clostridium difficile Infection

  2012cites this paper
• Antimicrobial Treatmdent of "Complicated" Intra-Abdominal Infections and The New IDSA Guidelines - A Commentary and an Alternative European Approach According to Clinical Definitions

  2011cites this paper
• Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases.

  2011cites this paper
• Treating Clostridium difficile infection with fecal microbiota transplantation.

  2011cites this paper
• Recurrent Clostridium difficile Infection

  2011cites this paper
• In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

  2011cites this paper
• Antimicrobial treatment of anaerobic infections

  2011cites this paper
• Clostridium difficile Returns with a Vengeance

  2011cites this paper
• Fidaxomicin

  2011cites this paper
• Development and Evaluation of an Ovine Antibody-Based Platform for Treatment of Clostridium difficile Infection

  2011cites this paper
• Binding of Clostridium difficile toxins to human milk oligosaccharides.

  2011influential citation
• Distribution and frequency of myeloid and t cell populations in the small intestine of newborn and weaned calves

  2011cites this paper
• The Pathogenesis of Clostridium difficile infection

  2011cites this paper
• Bactériothérapie clostridiale environnementale et formulations associées et leurs procédés de fabrication et d'utilisation

  2011cites this paper
• Lack of health insurance coverage for oral vancomycin: it's time to tackle the elephant in the room.

  2011cites this paper
• Clostridium difficile infection in 2010: Advances in pathogenesis, diagnosis and management of CDI

  2011cites this paper
• Trends in antimicrobial resistance in intensive care units in the United States

  2011cites this paper
• Treatment of refractory and recurrent Clostridium difficile infection

  2011cites this paper
• Current epidemiology and treatment of Clostridium difficile infection

  2010cites this paper
• Polyclonal Immunoglobulins and Hyperimmune Globulins in Prevention and Management of Infectious Diseases Keywords Ivig Immunoglobulin Sepsis Toxic Shock Cytomegalovirus Viral Hepatitis

  year unknowncites this paper